Jyong Biotech (MENS) Debt Ratio (2024 - 2025)
Jyong Biotech (MENS) posted quarterly Debt Ratio of 0.05 for Q4 2025, down 85.07% year-over-year from 0.33 in Q4 2024, and down 19.54% quarter-over-quarter from 0.06 in Q2 2025.
Jyong Biotech (MENS) Debt Ratio (2024 - 2025) Analysis & Trends
Jyong Biotech's Debt Ratio history runs 2 years deep, the most recent figure standing at 0.05 for Q4 2025.
- In Q4 2025, Debt Ratio fell 85.07% year-over-year to 0.05; the TTM figure through Dec 2025 stood at 0.05 (down 85.07% YoY), while the FY2025 annual figure was 0.05, down 85.07% from the prior year.
- Debt Ratio for Q4 2025 stood at 0.05, down from 0.06 in the prior quarter.
- The five-year high for Debt Ratio was 0.33 in Q4 2024, with the low at 0.05 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.05 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 0.05 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 0.12 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 0.03 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 0.26 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.47 |
| 10 | Jyong Biotech | 159.89 Mn | 159.89 Mn | - | 0.10 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.05 |
| Jun 30, 2025 | 0.06 |
| Dec 31, 2024 | 0.33 |